Abstract
In order to explore structure-activity relationship (SAR) associated with xanthone framework, a series of prenylated xanthone derivatives 2-9 was synthesized from the key building block 1,3,6,8-tetrahydroxyxanthone 1 and evaluated for their in vitro growth inhibitory activities against HeLa and MDA-MB-231 human cancer cell lines. The in vitro evidence indicated that the inhibitory activity was significantly influenced by the position and number of linked group on the xanthone skeleton, and the presence of chroman-4-one moiety in the xanthone scaffold was found to be critically important for strong cytotoxic activity. The novel 2H-xanthene-3,9-dione analogues 3 and 4 were reported to elicit potent activities comparable to those of standard drugs doxorubicin and cisplatin. This preliminary investigation has highlighted the therapeutic potential of 2H-xanthene-3,9-dione derivatives to be exploitable as lead compound for the development of potent HeLa and MDA-MB-231 cancer cell inhibitors.
Keywords: Cytotoxicity, 2H-xanthene-3,9-dione scaffold, 2H-xanthene-3,6,9(7H)-trione scaffold, Inhibitory activity, Synthesis, Xanthone derivatives, SAR, Xanthone, HeLa, MDA-MB-231, Cancer, prenylated, anti-inflammatory, 1,3-dihydroxyxanthone, phloroglucinol, acylphloroglucinols
Letters in Drug Design & Discovery
Title: Synthesis and SAR Study of Prenylated Xanthone Analogues as HeLa and MDA-MB-231 Cancer Cell Inhibitors
Volume: 8 Issue: 6
Author(s): Chan Kiang Lim, Lai-Yeng Tho, Cheng Hoe Lim, Yang Mooi Lim, Syed Adnan Ali Shah and Jean-Frederic Faizal Weber
Affiliation:
Keywords: Cytotoxicity, 2H-xanthene-3,9-dione scaffold, 2H-xanthene-3,6,9(7H)-trione scaffold, Inhibitory activity, Synthesis, Xanthone derivatives, SAR, Xanthone, HeLa, MDA-MB-231, Cancer, prenylated, anti-inflammatory, 1,3-dihydroxyxanthone, phloroglucinol, acylphloroglucinols
Abstract: In order to explore structure-activity relationship (SAR) associated with xanthone framework, a series of prenylated xanthone derivatives 2-9 was synthesized from the key building block 1,3,6,8-tetrahydroxyxanthone 1 and evaluated for their in vitro growth inhibitory activities against HeLa and MDA-MB-231 human cancer cell lines. The in vitro evidence indicated that the inhibitory activity was significantly influenced by the position and number of linked group on the xanthone skeleton, and the presence of chroman-4-one moiety in the xanthone scaffold was found to be critically important for strong cytotoxic activity. The novel 2H-xanthene-3,9-dione analogues 3 and 4 were reported to elicit potent activities comparable to those of standard drugs doxorubicin and cisplatin. This preliminary investigation has highlighted the therapeutic potential of 2H-xanthene-3,9-dione derivatives to be exploitable as lead compound for the development of potent HeLa and MDA-MB-231 cancer cell inhibitors.
Export Options
About this article
Cite this article as:
Kiang Lim Chan, Tho Lai-Yeng, Hoe Lim Cheng, Mooi Lim Yang, Adnan Ali Shah Syed and Faizal Weber Jean-Frederic, Synthesis and SAR Study of Prenylated Xanthone Analogues as HeLa and MDA-MB-231 Cancer Cell Inhibitors, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906820
DOI https://dx.doi.org/10.2174/157018011795906820 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Drug Transport Across the Placenta
Current Pharmaceutical Biotechnology Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone)
Current Rheumatology Reviews Effect of Lapachol on the Inhibition of Matrix Metalloproteinase Related to the Invasion of Human Fibrosarcoma Cells
Current Molecular Pharmacology The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Chemical Biology: Past, Present and Future
Current Chemical Biology Chalcones Incorporated Pyrazole Ring Inhibit Proliferation, Cell Cycle Progression, Angiogenesis and Induce Apoptosis of MCF7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry TGF-β in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma
Current Pharmaceutical Design Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets Small Molecules as SIRT Modulators
Mini-Reviews in Medicinal Chemistry Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Strategies for Preparing Different Types of Lipid Polymer Hybrid Nanoparticles in Targeted Tumor Therapy
Current Pharmaceutical Design 2(3)-Aryl-thio(oxy)-methylquinoxaline Derivatives: A New Class of P-Glycoprotein-Mediated Drug Efflux Inhibitors
Medicinal Chemistry TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets